Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 22 June 2025 - 24 September 2025

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

Stock Performance and Valuation Metrics uniQure’s stock performance in 2025 has been remarkably strong, capped by the explosive move on Sep. 24 after the Huntington’s data release. Prior to the announcement, QURE was trading in the mid-teens (around ~$14–$15) ts2.tech – already up over 100% year-to-date as anticipation for the trial results built. When the pivotal results hit, trading was halted pre-market due to pending news…
24 September 2025
·
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

QURE Stock Update and Analysis as of September 24, 2025 Latest News and Catalysts (September 2025) Historic Huntington’s Results: On September 24, 2025, uniQure revealed landmark Phase I/II trial results for its Huntington’s disease gene therapy AMT-130. In patients treated with a one-time injection of AMT-130, disease progression was significantly slowed – by about 75% over three years for those on the high dose Reuters. Treated…
24 September 2025
···
Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Lyme Disease on the Rise – And Why Mice Matter Lyme disease is often called a “plague” on Nantucket. The tiny Massachusetts island, famed for its beaches, has one of the nation’s highest infection rates Mit. About 15% of Nantucket’s residents have contracted Lyme disease, which causes fevers, rashes, swollen joints, and even nerve damage Cbsnews Cbsnews. The culprit is…
23 September 2025
·
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

In-Depth Report COVID-19 Vaccines and U.S. Public Health Upheaval Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines (by Pfizer–BioNTech, Moderna, and Novavax) updated for the 2025–26 season Reuters. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime…
28 August 2025
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the news cycle.) Public Health & Policy Highlights Sources: Key information in this report is drawn from reputable industry and news…
20 August 2025
··
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Sector – Big Deals, Funding, and FDA Drama Pharma & Drug Development – Approvals, Showdowns, and Safety Signals Medical & Clinical Updates – Guidelines and Safety Notices Public Health & Policy – Vaccine Rift, Medicare Cuts, and Wellness Initiatives Sources: Key news and expert quotes were gathered from Fierce Biotech Fiercebiotech Fiercebiotech, Fierce Pharma Fiercepharma Fiercepharma, Fierce Healthcare Fiercehealthcare…
19 August 2025
··
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia, the first new fibromyalgia therapy…
16 August 2025
···
Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Drug Approvals & Regulatory Developments (In Europe, regulators also made news: the EMA’s committee recommended approving darolutamide (Bayer’s Nubeqa) with hormone therapy for metastatic prostate cancer based on positive Phase 3 data Onclive.) Clinical Trials & Research Breakthroughs Public Health & Policy Industry & Business Updates Sources: Key information and quotes in this report were drawn from Reuters news wires…
9 August 2025
··
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug…
27 June 2025
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer Inc., in collaboration with BioNTech, co-developed the first FDA-approved mRNA COVID-19 vaccine, Comirnaty. Roche Holding AG is the world’s largest biotech company and a leader in oncology treatments (Herceptin) and diagnostics. Moderna, Inc. pioneered mRNA vaccine technology and its COVID-19 vaccine was among the first mRNA medicines approved, while expanding mRNA therapeutics for cancer and rare diseases. Illumina, Inc.…
22 June 2025
·
1 … 22 23 24

Stock Market Today

  • Jardine Matheson Holdings Repurchases 100,700 Shares at Average Price of $73.64
    February 2, 2026, 7:02 AM EST. Jardine Matheson Holdings Ltd (JMH) repurchased 100,700 of its ordinary shares on February 2, 2026. The shares were bought back at prices ranging from $73.465 to $73.7327 per share, with a weighted average price of $73.6397. Following cancellation of these shares, JMH's issued share capital now stands at 294,404,878 ordinary shares, each with one voting right. JMH holds no treasury shares. This transaction reflects JMH's ongoing capital management strategy and complies with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The share buyback reduces the total shares outstanding, potentially impacting shareholder value and voting power.
Go toTop